

# Understanding neurologist perspectives on the clinical meaningfulness of 'any point differences' on the Hammersmith Functional Motor Scale-Expanded in SMA

Leslie Nelson,<sup>1</sup> Natalie Land,<sup>2</sup> Melissa Culhane Maravic,<sup>2</sup> Thomas Brown,<sup>3</sup> Christabella Cherubino,<sup>3</sup> Mouhamed Gueye<sup>3</sup>

<sup>1</sup>University of Texas Southwestern Medical Center, Dallas, TX, USA; <sup>2</sup>Precision AQ, New York, NY, USA; <sup>3</sup>Scholar Rock, Inc., Cambridge, MA, USA

## INTRODUCTION

- Spinal muscular atrophy (SMA) is a severe neuromuscular disease characterized by the irreversible loss of spinal motor neurons and progressive skeletal muscle atrophy, leading to weakness and motor function decline<sup>1</sup>
- Despite substantial advances in diagnosis and treatment of SMA, patients with SMA report gaining muscle strength and stabilizing or achieving new motor function as significant unmet needs<sup>2,3</sup>
- SMA treatment efficacy is traditionally measured by motor function assessments, including the Hammersmith Functional Motor Scale-Expanded (HFMSSE)<sup>4</sup>; however, treatment impact on clinically meaningful change remains difficult to ascertain and usually requires additional insights from patients with SMA or their caregivers
- Identifying which motor function changes are clinically meaningful to patients with SMA, their caregivers, and providers will improve our understanding of the importance of specific motor function changes and their real-world impact on patients' daily lives


## OBJECTIVES

- Examine perspectives on clinically meaningful outcomes among providers (neurologists and physical therapists)
- Identify and understand which motor function changes on the HFMSSE are considered clinically meaningful to providers (neurologists and physical therapists)
- Inform future research on SMA to incorporate additional clinically meaningful endpoints
- Here, we focus on understanding neurologists' perspectives on the clinical meaningfulness of functional changes measured by the HFMSSE

## RESULTS

- Eleven of the 20 eligible providers interviewed were neurologists (Figure 2)
  - Neurologists' responses per HFMSSE task grouping are listed in Table 2
  - For outcomes from physical therapist interviews, please see poster 110, also by Nelson and colleagues

Figure 2. Neurologist demographics and characteristics



HFMSSE, Hammersmith Functional Motor Scale-Expanded; SD, standard deviation; SMA, spinal muscular atrophy.

Table 2. Number of neurologist responses for each HFMSSE task grouping

HFMSSE item number	Task	Neurologists (n=11)
1	1 Plinth/chair sitting	4
2	2 Long sitting, legs straight	5
3, 4	3 One hand to head in sitting 4 Two hands to head in sitting	6
5-9	5 Supine to side-lying 6, 7 Rolls prone to supine over R/L 8, 9 Rolls supine to prone over R/L	5
10, 14	10 Sitting to lying 14 Lying to sitting	5
11	11 Props on forearms	4
13	13 Props on extended arms	5
12, 17	12 Lifts head from prone 17 Lifts head from supine	7
15, 16	15 Four-point kneeling 16 Crawling	6
18-20	18 Supported standing 19 Unsupported standing 20 Stepping	9
21-27	21, 22 Hip flexion in supine (R/L) 23, 24 High kneeling to half kneel (R/L) 25, 26 High kneeling to stand leading with R/L leg 27 Stand to sit	6
28, 29	28 Squat 29 Jump 12"	2
30-33	30 Ascends stairs with rail 31 Descends stairs with rail 32 Ascends stairs without rail 33 Descends stairs without rail	3

HFMSSE, Hammersmith Functional Motor Scale-Expanded; L, left; R, right.

## METHODS

- 60-minute, web-based, in-depth qualitative interviews were conducted with providers (neurologists and physical therapists) experienced with treating SMA and using the HFMSSE; this analysis focuses on interviews with neurologists
- Neurologists meeting the inclusion criteria were eligible for study enrollment (Table 1)


Table 1. Inclusion criteria

Key inclusion criteria	Description
	Neurologists or pediatric neurologists with a Medical Doctor (MD) or Doctor of Osteopathy (DO) degree currently practicing in the United States
	Provides care/services to patients with SMA
	Reports being familiar or very familiar with HFMSSE
	Administers or uses results from the HFMSSE assessment to evaluate their patients with SMA ≥5 times per year
	Practicing neurology for ≥5 years

HFMSSE, Hammersmith Functional Motor Scale-Expanded; SMA, spinal muscular atrophy.

- A semistructured discussion guide was informed by a focused targeted literature review (Figure 1)
- The discussion guide included open-ended questions to elicit and examine perspectives and experiences on:
  - How clinical meaningfulness is interpreted
  - What constitutes meaningful change at the individual item level on the HFMSSE
  - How meaningful change in specific motor function abilities may impact the patient's ability to perform activities of daily living (ADLs), quality of life (QoL), independence, and psychosocial health
- Interview transcripts were analyzed using the constant comparative method, an iterative approach to aggregate and synthesize qualitative data

Figure 1. Study approach overview




FTLR, focused targeted literature review; SMA, spinal muscular atrophy.

- Neurologists' perspectives regarding HFMSSE score changes were centered on patient experiences
  - A change that significantly impacts a patient's functioning, independence, and QoL, particularly their ability to perform ADLs and other essential life tasks, is clinically meaningful (Figure 3)
  - Objective score changes may not always reflect true clinical relevance or what matters most to patients in terms of ADLs and QoL
  - Generally, any point differences or stability across functional tasks within the HFMSSE can represent meaningful indicators of functional and psychological impacts that influence a patient's independence and QoL (Figure 4)

Figure 3. Neurologist perspectives on clinical meaningfulness



Figure 4. Neurologist perspectives on clinically meaningful changes reflected in HFMSSE tasks



Neurologist quotes have been edited for readability. HFMSSE, Hammersmith Functional Motor Scale-Expanded.

## CONCLUSIONS

- Based on neurologists' responses, clinically meaningful change is best understood through a patient-centered perspective, where improvements or declines in daily functioning and independence are evaluated in the context of individual goals and lived experiences
- Neurologists generally agreed that any point differences or stability in HFMSSE scores, regardless of functional task, can reflect significant impacts on patients' independence and QoL, underscoring the importance of measuring and charting small changes
- Stability was generally regarded as important to patients' QoL and independence, as functional declines have meaningful negative impacts

## References

- Mercuri E, et al. *Nat Rev Dis Primers*. 2022;8(1):52.
- Cure SMA. 2023 State of SMA report. Accessed Feb 18, 2026. [https://www.curesma.org/wp-content/uploads/2025/04/State-of-SMA-Report2024\\_vWeb-1.pdf](https://www.curesma.org/wp-content/uploads/2025/04/State-of-SMA-Report2024_vWeb-1.pdf).
- Parsons JA, et al. *Ann Clin Transl Neurol*. 2025;12(10):2020-2035.
- Ramsey D, et al. *PLoS One*. 2017;12(2):e0172346.

## Acknowledgments

- This study was funded by Scholar Rock, Inc.
- Medical writing and editorial support were provided by Aidan Moriarty, PhD, and Dena McWain of Helios Global Group, and funded by Scholar Rock, Inc.
- Project management support was provided by Taryn Bosquez-Berger, PhD, CMPP, of Scholar Rock, Inc.
- We thank Rozanne Wilson, PhD, Claire Cagle, MPH, and Amal Jamaledine of Precision AQ for their important contributions to this project

## Disclosures

LN is a consultant for AveXis, Biogen Inc., F. Hoffmann-La Roche, Novartis, and Scholar Rock, Inc. NL is an employee of Precision AQ. MCM is an employee of Precision AQ and owns equity interest in Precision AQ's parent company, Precision Medicine Group. TB, CC, and MG are employees of and stockholders in Scholar Rock, Inc.



To download a copy of this poster, scan QR code.